Absorption of dietary cholesterol in the proximal region of the intestine is mediated by Niemann-Pick C1-like protein (NPC1L1) and is sensitive to the cholesterol absorption inhibitor ezetimibe (EZE). Although a correlation exists between EZE binding to NPC1L1 in vitro and efficacy in vivo, the precise nature of interaction(s) between NPC1L1, EZE, and cholesterol remain unclear. Here, we analyze the direct relationship between EZE analog binding to NPC1L1 and its influence on cholesterol influx in a novel in vitro system. Using the EZE analog [ 3 H]AS, an assay that quantitatively measures the expression of NPC1L1 on the cell surface has been developed. It is noteworthy that whereas two cell lines (CaCo-2 and HepG2) commonly used for studying NPC1L1-dependent processes express almost undetectable levels of NPC1L1 at the cell surface, polarized Madin-Darby canine kidney (MDCKII) cells endogenously express 4 ϫ 10 5 [ 3 H]AS sites/ cell under basal conditions. Depleting endogenous cholesterol with the HMG CoA reductase inhibitor lovastatin leads to a 2-fold increase in the surface expression of NPC1L1, supporting the contention that MDCKII cells respond to changes in cholesterol homeostasis by up-regulating a pathway for cholesterol influx. However, a significant increase in surface expression levels of NPC1L1 is necessary to characterize a pharmacologically sensitive, EZE-dependent pathway of cholesterol uptake in these cells. Remarkably, the affinity of EZE analogs for binding to NPC1L1 is almost identical to the IC 50 blocking cholesterol flux through NPC1L1 in MDCKII cells. From a mechanistic standpoint, these observations support the contention that EZE analogs and cholesterol share the same/overlapping binding site(s) or are tightly coupled through allosteric interactions.
3
H]AS, an assay that quantitatively measures the expression of NPC1L1 on the cell surface has been developed. It is noteworthy that whereas two cell lines (CaCo-2 and HepG2) commonly used for studying NPC1L1-dependent processes express almost undetectable levels of NPC1L1 at the cell surface, polarized Madin-Darby canine kidney (MDCKII) cells endogenously express 4 ϫ 10 5 [ 3 H]AS sites/ cell under basal conditions. Depleting endogenous cholesterol with the HMG CoA reductase inhibitor lovastatin leads to a 2-fold increase in the surface expression of NPC1L1, supporting the contention that MDCKII cells respond to changes in cholesterol homeostasis by up-regulating a pathway for cholesterol influx. However, a significant increase in surface expression levels of NPC1L1 is necessary to characterize a pharmacologically sensitive, EZE-dependent pathway of cholesterol uptake in these cells. Remarkably, the affinity of EZE analogs for binding to NPC1L1 is almost identical to the IC 50 blocking cholesterol flux through NPC1L1 in MDCKII cells. From a mechanistic standpoint, these observations support the contention that EZE analogs and cholesterol share the same/overlapping binding site(s) or are tightly coupled through allosteric interactions.
Whole-body cholesterol homeostasis is maintained through three major pathways: de novo synthesis, intestinal absorption, and biliary excretion. Absorption of dietary and biliary cholesterol occurs in the proximal jejunum of the small intestine (Grundy, 1983) , and this process is blocked by ezetimibe, a drug used for the treatment of hypercholesterolemia. Ezetimibe, a potent cholesterol and phytosterol uptake inhibitor, effectively lowers circulating plasma cholesterol in humans by 15 to 20% (Bays et al., 2001; Dujovne et al., 2002; Knopp et al., 2003) and its coadministration with HMG CoA reductase inhibitors (statins), inhibitors of cholesterol synthesis, leads to further reductions in cholesterol plasma levels (Davidson et al., 2002; Gagné et al., 2002; Ballantyne et al., 2003; Kerzner et al., 2003; Melani et al., 2003) .
By searching expressed sequence tag databases for the presence of a sterol-sensing domain, a plasma membrane secretion signal, and enriched expression in intestinal enterocytes, the Niemann-Pick C1-Like 1 (NPC1L1) protein was identified in 2004 as a potential candidate gene product for the ezetimibe-sensitive pathway of cholesterol absorption. Mice deficient in NPC1L1 were found to have ϳ70% reduction in sterol absorption, the residual component being in-sensitive to ezetimibe (Altmann et al., 2004) . These findings convincingly demonstrated that NPC1L1 is a critical component of cholesterol uptake in enterocytes (Altmann et al., 2004) . With the use of enterocyte brush-border membranes from several species, including NPC1L1 knockout mice, or membranes derived from cells expressing recombinant NPC1L1, radioligand binding studies with ezetimibe convincingly established NPC1L1 as the direct target of ezetimibe in vivo (Garcia-Calvo et al., 2005) .
Probing the molecular mechanism of NPC1L1 action is complicated by the difficulties associated with culturing enterocytes in vitro (Simon-Assmann et al., 2007) . Therefore, researchers have developed a variety of alternative systems, including brush-border membrane vesicles from enterocytes (Knöpfel et al., 2007; Labonté et al., 2007) , cell lines heterologously expressing recombinant NPC1L1 (Davies et al., 2005; Iyer et al., 2005; Yu et al., 2006; Brown et al., 2007; Hawes et al., 2007) , cell lines endogenously expressing NPC1L1, such as CaCo-2 (Davies et al., 2005; During et al., 2005; Garmy et al., 2005; van der Veen et al., 2005; Duval et al., 2006; Sané et al., 2006; Alrefai et al., 2007; Field et al., 2007; Mathur et al., 2007; Yamanashi et al., 2007) and HepG2 (Davies et al., 2005; Yu et al., 2006) , and functional complementation in Caenorhabditis elegans (Smith and Levitan, 2007) . By overexpressing NPC1L1 in McArdles RH7777 hepatoma cells (Yu et al., 2006) and CaCo-2 enterocyte-like cells (Yamanashi et al., 2007) , it has been possible to establish assays with which to monitor a component of EZEsensitive cholesterol influx (Yu et al., 2006; Yamanashi et al., 2007) . However, pharmacological validation of these cell lines and insight into the mechanism by which EZE analogs inhibit cholesterol flux through NPC1L1 remain quite limited.
In this study, we attempt to address the relationship between binding of EZE analogs to NPC1L1 and their effect on cholesterol flux in vitro, using a combination of novel tools. A cell-based binding assay that can accurately determine the surface expression of NPC1L1 has been established with the use of the high-affinity EZE analog, [
3 H]AS. It is noteworthy that whereas CaCo-2 and HepG2 cells display no discernible [ 3 H]AS binding, a polarized dog kidney cell line (MDCKII) was found to express significant amounts of endogenous NPC1L1 at the cell surface in a manner that can be modulated in response to changes in endogenous cholesterol levels. Overexpression of either dog or human NPC1L1 in MDCKII cells provides an assay with which to monitor cholesterol flux, which is pharmacologically modulated by EZE analogs. It is noteworthy that the affinity of EZE analogs for binding to NPC1L1 is almost identical to their IC 50 values, blocking cholesterol flux through NPC1L1. Viewed from a mechanistic perspective, these data support the notion that EZE analogs and cholesterol share the same/overlapping binding site(s) on NPC1L1 or that these sites are tightly coupled through allosteric interactions.
Materials and Methods

Materials.
Restriction enzymes and Pfusion polymerase were from New England Biolabs (Ipswich, MA). pCDNA5-FRT-TOPO, pCDNA5-FRT, SuperScript II, and STBL2 competent cells were purchased from Invitrogen (Carlsbad, CA,). Synthetic oligonucleotides were synthesized by Integrated DNA Technologies, Inc. (Coralville, IA). Tri Reagent for RNA preparation was from Molecular Research Center (Cincinnati, OH). dNTPs were purchased from Roche Diagnostics (Indianapolis, IN), RNeasy columns from QIAGEN (Valencia, CA), and Chromaspin columns from Clontech (Mountain View, CA). Dye terminator sequence reactions were performed with the ABI Big Dye 3.1 sequencing kit and analyzed with an ABI3100 genetic analyzer, both from Applied Biosystems (Foster City, CA). Human embryonic kidney (HEK) 293, HepG2, LLC-PKI, and CaCo-2 cell lines were from American Type Culture Collection (Manassas, VA). MD-CKII cells were from Dr. Piet Borst (Netherlands Cancer Institute, Amsterdam, The Netherlands) (Louvard, 1980) and TsA201 cells were a gift of Dr. Robert DuBridge (Pdl Biopharm Inc., Freeman, CA). Fugene6 transfection reagent was from Roche. Generation and maintenance of a stable cell line expressing rat NPC1L1 in HEK293 cells (rNPC1L1/HEK293) (Garcia-Calvo et al., 2005) , and procedures for handling TsA201 cells and their transfection with FuGENE6 have been described previously (Hanner et al., 2001) . LLC-PKI cells were maintained in medium 199 ϩ GlutaMax, CaCo-2 and MDCKII cells were maintained in in DMEM ϩ Glutamax (Sigma, St. Louis, MO), and HepG2 cells were maintained in Eagle's minimum essential medium. All media were supplemented with 10% FBS, penicillin, and streptomycin, and cells were grown at 37°C in 5% CO 2 .
Ezetimibe (EZE), ezetimibe glucuronide (EZE-gluc), and the EZEgluc-enantiomer (ent-1) were prepared as described previously (Garcia-Calvo et al., 2005) . (Goulet et al., 2005) are named using the IUPAC convention (Fig. 1) . All other reagents were obtained from commercial sources and were of the highest purity commercially available.
Preparation of [ 3 H]AS.
A solution of PS (2 mg, 0.0028 mmol) in 0.8 ml of anhydrous N,N-dimethylformamide was degassed at dry ice/acetone temperature in the presence of 5 mg of 10% Pd/C [10% (dry basis) on activated charcoal, wet, Degussa type; Sigma-Aldrich]. The mixture was stirred at 0°C for 2 h under 240 mm Hg of carrierfree tritium gas (1.2 Ci; American Radiolabeled Chemicals, St. Louis, MO). Unreacted tritium gas was removed, the catalyst was filtered 
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at ASPET Journals on June 20, 2017 molpharm.aspetjournals.org through a syringe-less filter device (0.45 m polytetrafluoroethylene; Autovial; Whatman, Clifton, NJ), and the solvent and labile tritium were removed by concentration to near dryness. This procedure was repeated three times to ensure complete reduction of the C-C triple bonds and ensure high specific activity. The dried residue was resuspended in 2 ml of ethanol and purified by HPLC (HPLC column, 9.4 3 H]AS was added to either the apical or basolateral compartment of the Transwell membrane, at a concentration of 1 nM, and incubation took place for 2 h at 37°C. Thereafter, both apical and basolateral compartments were washed three times with PBS, and the transwell filter was cut out and its associated radioactivity determined using a ␤-counter. Data from saturation, competition and ligand dissociation experiments were analyzed as described previously (Knaus et al., 1995; Priest et al., 2004 Cloning of Dog NPC1L1 and Expression in MDCKII Cells. Total RNA was isolated from 3 ϫ 10 7 MDCKII cells using TriReagent and purified with RNeasy columns. Single-stranded cDNA was synthesized from total RNA using SuperScript II and random hexamer primers and subsequently purified with Chromaspin 200 following conditions suggested by the manufacturer (Clontech). BLAST searches of public DNA databases with the human NPC1L1 protein sequence identified a partial sequence for dog NPC1L1. Based on alignments with multiple sequences for NPC1L1, this dog sequence was missing its 3Ј region. Using the partial dog NPC1L1 sequence and the human sequence, genomic sequence for dog NPC1L1 was identified. Translation of an open reading frame extracted from the genomic sequence was in good agreement with human and bovine NPC1L1. Therefore, the primers dNL1-sense (CTGCACAGGGATG-GCGGACACTGGCCTGAG) and dNL1-antisense (CTCCGGCT-TCATCAGAGGTCCGGTCCACTGC) were designed to amplify a product of approximately 4 kilobase pairs using Pfusion DNA polymerase in a high-fidelity PCR reaction performed with single stranded cDNA and an extension time of 135 s and 33 cycles. PCR products from several reactions were combined and purified before cloning into the vector pCDNA5/FRT TOPO. Sequencing of several plasmids containing insert revealed a PCR product for the complete coding region of dog NPC1L1, with start and putative stop codons. Because the insert consistently integrated into pCDNA5/FRT TOPO in the reverse orientation, it was isolated by restriction digest and directionally cloned into the vector pCDNA5/FRT.
MDCKII-Flp cells were generated by stably transfecting with pFRT/lacZeo cDNA (Invitrogen) using Lipofectamine 2000 (Invitrogen) according to manufacturer's instructions. Forty-eight hours after transfection, cells were selected in Zeocin (700 g/ml), and resulting cell colonies were isolated and assayed for ␤-galactosidase activity (␤-galactosidase assay kit; Invitrogen). The clone with the highest activity was used as the host cell line in subsequent transfections. Dog and human NPC1L1/MDCKII II-Flp stable cell lines were generated by transfecting MDCKII-Flp cells with pCDNA5/ FRT-dog NPC1L1 or pCDNA5/FRT-human NPC1L1 plasmids using Lipofectamine, followed by selection on 200 g/ml Hygromycin B. Clones were isolated with cloning rings and selected for levels of [ 3 H]AS binding in the absence or presence of 10 mM sodium butyrate to identify cells expressing high amounts of human or dog NPC1L1.
RNA Extraction, Reverse Transcription and Quantitative Real-Time PCR. For total RNA isolation and preparation, MDCKII cells were washed once in PBS and immersed in TriReagent. The RNA preparation was performed according to the manufacturer's protocol. In brief, chloroform was added to the cells, and the aqueous phase containing RNA was separated from DNA and protein by centrifugation. The aqueous phase was processed using an RNEasy MicroKit (QIAGEN) yielding pure total RNA and dissolved in water. To allow use of comparable amounts of RNA for cDNA preparation, the RNA concentration in all samples was measured with an Agilent BioAnalyzer 2100 (Agilent Technologies, Palo Alto, CA). Standard reagents (ABI TaqMan reverse transcription reagents; Applied Biosystems) were used to synthesize cDNAs. A maximum of 500 ng of RNA in 100 l was used for a single reverse transcriptase reaction.
QRT-PCR was conducted using TaqMan technology with oligonucleotide primers and probes custom-ordered from ABI. TaqMan reactions were performed according to standard protocols. Data were analyzed using the standard curve method as described in Applied Biosystems' documentation on Relative Quantitation of Gene Expression for ABI PRISM 7700. The relative expression level of the gene of interest was computed from each experimental sample using a housekeeping gene (18s; Applied Biosystems) as an internal standard. Each experimental sample was quantified in three independent cDNA preparations and repeated at least two times on different plates.
Cell-Based [ 3 H]Cholesterol or [ 3 H]Sitosterol
Flux. Flux assays were performed essentially as described by Yu et al. (2006) . In brief, cell growth medium was completely aspirated and replaced with 200 l of 5% lipoprotein-deficient serum (LPDS) containing the appropriate concentration of compound and incubated at 37°C for 3 h in a 5% CO 2 incubator. Media was subsequently aspirated, and cells were incubated in 200 l of 0 to 5.5% methyl-␤-cyclodextrin (␤mCD), dissolved in 5% LPDS, and filtered through a 0.22 M filter, at 37°C for 45 min in a 5% CO 2 incubator. Media was removed and cells were washed twice with 125 l of 5% LPDS followed by addition of diolabeled Chemicals) complexed to bovine serum albumin in 5% LPDS (Yu et al., 2006) . After a 45-min incubation, cells were washed twice with DMEM, and 1% SDS was added. Solubilized cell content was transferred to vials for radioactive analyses. (Fig. 2B ). The nonspecific binding component was time-independent and has been subtracted from the experimental data. A semilogarithmic transformation of the data yielded a linear dependence (Fig. 2B , inset), as expected for a pseudo-first-order reaction, and the slope of this line gives k obs of 0.0208 min Ϫ1 . The association rate constant, k 1 , calculated as described under Materials and Methods, was 2.4 ϫ 10 6 M Ϫ1 min Ϫ1 . Dissociation of cell bound [
Results
Binding of [
3 H]AS, initiated by addition of 100 M Eze-Gluc, followed a single monoexponential decay with a t 1/2 of ϳ3 h, corresponding to k Ϫ1 of 0.0059 min Ϫ1 (Fig. 2C) . The K d calculated from these rate constants was 2.46 nM, a value similar to that determined under equilibrium binding conditions (4.62 nM). These kinetic observations indicate that [ 3 H]AS bound to a single class of sites through a simple bimolecular and fully reversible reaction.
Binding of [ 3 H]AS to rat NPC1L1/HEK293 cells was inhibited in a concentration-dependent manner by increasing concentrations of AS, PS, EZE-gluc, and EZE (Fig. 2D) . K i values, determined as described under Materials and Methods, are presented in Table 1 and display the expected rank-order of potency for interaction of these ligands with rat NPC1L1 (Garcia-Calvo et al., 2005) . The EZE-gluc enantiomer ent-1 did not significantly inhibit the binding of [ 3 H]AS to rat NPC1L1/HEK293 cells at concentrations up to 50 M (Fig.  2D, inset) .
To confirm that the noncovalent interaction between [ 3 H]AS and rat NPC1L1 occured at the cell surface, rNPC1L1/HEK293 cells were incubated with [ 3 H]AS and subsequently acidwashed with DMEM at pH 3.5. Such an approach has previously been used to characterize cell-surface noncovalent interactions (Hopkins and Trowbridge, 1983; Chen et al., 1998) . Treatment of cells at pH 3.5 for 1, 5, or 15 min led to dissociation of Ͼ70, 80, and 85% of bound [ 3 H]AS, respectively (Fig. 2E) , indicating that the majority of radioligand binding sites were present at the cell surface and not at intracellular compartments. It is noteworthy that after acid removal, incubation of cells with [ 3 H]AS for 2 h at 37°C causes re-binding of ligand at levels similar to those observed before the acid wash (Fig. 2E) , indicating that the loss of radioligand after acid treatment was not due to any significant loss in cell integrity. All data, taken together, strongly indicate that the cell-based binding assay defined cell-surface expression of NPC1L1. (Fig. 4A) , from which k 1 of 1.63 ϫ 10 7 M Ϫ1 min Ϫ1 could be calculated. Dissociation of cell-bound [ 3 H]AS, initiated by addition of 100 M Eze-Gluc, followed a single monoexponential decay with a t 1/2 of ϳ3 h, corresponding to k Ϫ1 of 0.0023 min Ϫ1 (Fig. 4B) . The K d calculated from these rate constants, 0.14 pM, was similar to that determined under equilibrium binding conditions, 0.59 Ϯ 0.07 nM, (Fig. 3B) .
As previously observed with rNPC1L1/HEK293 cells, acid washing of MDCKII cells equilibrated with [
3 H]AS leads to dissociation of up to 85% of the radioligand (Fig. 4C) . Likewise, after acid removal, [
3 H]AS bound to MDCKII cells at levels similar to those obtained before acid treatment, indicating that the loss of binding was due not to any significant loss in cell integrity but to disruption of noncovalent interactions between ligand and cell surface expressed NPC1L1-like activity.
Because MDCKII cells, like enterocytes and hepatocytes, are polarized epithelial cells demonstrating microvilli and tight junctions, the distribution of [ (Fig.  4D) . However, when the same amount of ligand was added to the basolateral side of the Transwell, corresponding to the basolateral surface of the MDCKII cells, specific [
3 H]AS binding was significantly lower than in the previous situation (Fig. 4D) Cloning and Pharmacological Characterization of the NPC1L1-Like Activity from MDCKII Cells. Given that [
3 H]AS binding data strongly suggest the presence of NPC1L1 in the apical membrane of MDCKII cells, total RNA was isolated from MDCKII cells, and a full-length clone containing a single amino acid change from the predicted dog NPC1L1 genomic sequence (I864M) was isolated. This clone is in agreement with another recently reported dog NPC1L1 sequence (Hawes et al., 2007) with the exception of a single amino acid change (L63P). Dog NPC1L1, like its homologs in other species, was predicted to have 13 transmembrane domains, the N terminus being extracellular and the C terminus, intracellular. Likewise, the sterol-sensing domain was conserved with that found in other species. These data strongly suggest that the NPC1L1 to these cells was then characterized (Fig. 4F and (Fig. 5A, I and II). Incubation of MDCKII cells with 4 M lovastatin and 10% FBS led to a 40% increase in the surface expression of NPC1L1 at the 72-h time point (Fig. 5A, I ). In contrast, lovastatin treatment tripled [
3 H]AS binding in cells grown in 5% LPDS at 72 h (Fig. 5A, II (Fig. 5B) .
To gain insight into the mechanism underlying the lovastatin-induced increase in [ 3 H]AS binding to cells grown in 5% LPDS, we determined the amount of NPC1L1 and HMG CoA reductase message by QRT-PCR. QRT-PCR indicated that 4 M lovastatin led to an increase in the amount of HMG CoA reductase transcript in MDCKII cells grown in either 10% FBS or 5% LPDS (Fig. 5C, I and II). Furthermore, over time, QRT-PCR demonstrated that the amount of dog NPC1L1 transcript increased in MDCKII cells grown in either 10% FBS or 5% LPDS (Fig. 5C, III and IV) . However, when MD-CKII cells were grown in 10% FBS, 4 M lovastatin did not increase transcription of dog NPC1L1 above that observed in untreated cells (Fig. 5C, III) . In contrast, when MDCKII cells were grown in 5% LPDS, 4 M lovastatin increased dog NPC1L1 transcription above that observed in untreated cells (Fig. 5C, IV) .
Overexpression of NPC1L1 in MDCKII-Flp cells Was Necessary for EZE-Like-Sensitive [ 3 H]Cholesterol Flux.
To validate MDCKII cells as an appropriate surrogate system for monitoring NPC1L1-dependent processes, we evaluated their ability to perform EZE-sensitive cholesterol flux using a protocol similar to that reported recently (Yu et al., 2006) . This assay makes use of the ability of ␤mCD to deplete membranebound cholesterol. (Fig. 6A,  I ). In an attempt to improve the assay window, we generated hNPC1L1/MDCKII-Flp, a stable MDCKII-Flp cell line overexpressing human NPC1L1. [ (Fig. 6A, II) . It is noteworthy that in hNPC1L1/ MDCKII-Flp cells, treatment with 4% ␤mCD led to a significant increase in the amount of [ 3 H]cholesterol influx into cells that was almost completely blocked in the presence of 10 M PS (Fig. 6A, III) . Addition of 4 mM sodium butyrate (Chen et al., 1997) had no significant effect on the amount of [ (Fig. 6B, I ). After induction of dNPC1L1/MDCKII-Flp cells for 24 h with 4 mM sodium butyrate (Chen et al., 1997) , K d remained similar at 1.53 nM; however, the B max rose to 384 pM (1.83 ϫ 10 6 sites/cell; Fig. 6B, II) . It is noteworthy that after NPC1L1 induction, treatment of the cells with 4% ␤mCD led to a significant increase in the amount of [ 3 H]cholesterol entering cells, and this process was almost completely blocked by 10 M PS (Fig. 6B, III) .
Relationship between EZE Analog Binding to NPC1L1 and Reduction in Cholesterol and Sitosterol Flux. To further understand the [ (Fig. 7A, III and IV (Fig. 7B, I ) [PS (5 nM)Ͼ ϾEZE-gluc (209 nM)Ͼ Ͼent-1 (N.D., Ͼ 100 M)] correlates well with the IC 50 values of these compounds for blocking [
3 H]cholesterol influx (Fig. 7B, II) [PS (7 nM)Ͼ ϾEZE-Gluc (300 nM)Ͼ Ͼ ent-1 (N.D., Ͼ 100 M)] into hNPC1L1/MDCKIIFlp cells. These data, taken together, strongly support the notion that MDCKII cells represent a powerful functional system for studying NPC1L1-dependent processes and provide insight into the mechanism of EZE inhibition of cholesterol flux.
Discussion
To understand the molecular mechanism of EZE-sensitive NPC1L1 dependent cholesterol flux in vitro, researchers have developed surrogate cell lines for the enterocyte that have been characterized either on the basis of NPC1L1 localization [using fusion to fluorescent proteins (Davies et al., 2005; Yu et al., 2006; Brown et al., 2007) , immunocytochemistry (Davies et al., 2005) , cell-surface biotinylation (Davies et al., 2005) or immunoblotting (Iyer et al., 2005; Sané et al., 2006) (Sané et al., 2006; Yu et al., 2006; Field et al., 2007; Yamanashi et al., 2007) or effects on transcripts after siRNA reduction of NPC1L1 expression (Sané et al., 2006) ]. Here, we reasoned that an appropriate cell line for studying NPC1L1-dependent processes will express NPC1L1 at the cell surface for interaction with EZE-like compounds. To identify such a system, a cell-based binding assay that allows the quantitative anal- ]AS bound to rat NPC1L1 at the plasma membrane of rNPC1L1/HEK293 cells. First, the relatively slow association of radioligand exhibits monoexponential kinetics, indicating that binding occurs to a single class of NPC1L1 binding sites. Given the extremely low background of radioligand binding to untransfected HEK293 cells and the hydrophilic properties of the glucuronide moiety, it is unlikely that [ 3 H]AS would passively diffuse across the plasma membrane to bind to a single population of intracellular NPC1L1 sites. Second, dissociation of radioligand is almost complete and exhibits monoexponential kinetics, consistent with release from a single pool of binding sites. Third, acid washing of cells discriminates between noncovalent interactions occurring at the cell surface or inside the cell. The ability to wash off Ͼ 75% of bound radioligand with a 1 min of acid treatment and its subsequently rebinding after acid removal supports the contention that the cell-based binding assay measures the cell surface interaction between NPC1L1 and EZE-like compounds (Hopkins and Trowbridge, 1983) . These studies extend a recent report documenting the use of a fluorescent EZE analog to monitor equilibrium binding to various species of NPC1L1 expressed in cells (Hawes et al., 2007) .
We used binding of [ 3 H]AS to explore surface expression of NPC1L1 in the widely used CaCo-2 (Davies et al., 2005; During et al., 2005; Garmy et al., 2005; van der Veen et al., 2005; Duval et al., 2006; Sané et al., 2006; Alrefai et al., 2007; Field et al., 2007; Mathur et al., 2007; Yamanashi et al., 2007) and HepG2 (Davies et al., 2005; Yu et al., 2006) cells. However, we found that under basal conditions, there was not detectable surface expression of NPC1L1 in these cell lines. Such low surface expression of NPC1L1 is consistent with reports indicating that the majority of NPC1L1 is expressed intracellularly under basal conditions (Davies et al., 2005; Yu et al., 2006) . Based on the lower limit of sensitivity of our assay, we speculate that the endogenous expression of NPC1L1 in the apical membrane of CaCo-2 cells (Sané et al., 2006) H]AS to define surface NPC1L1 expression will allow the in vitro relationship between subcellular localization of NPC1L1 and EZE-effects on NPC1L1-dependent processes to be quantitatively explored across cell systems.
In contrast to CaCo-2 and HepG2 cells, the cell-based radioligand binding assay identified polarized, epithelial MD- CKII cells as a robust source of endogenous NPC1L1-like activity with similar pharmacology to rat NPC1L1. Furthermore, and in agreement with a recent study, comparing the binding of glucuronidated ezetimibe to multiple species of NPC1L1 orthologs (Hawes et al., 2007) , MDCKII cells, derived from dog distal convoluted tubule, were found to consistently bind EZE analogs more potently than rat NPC1L1 expressed in HEK293 cells. It is noteworthy that [ 3 H]AS binding to MDCKII cells occurs almost exclusively at the apical surface, consistent with the apparent localization of NPC1L1 in both enterocytes (Altmann et al., 2004) and hepatocytes (Yu et al., 2006) . Direct measurements using [ 3 H]AS indicate that serumdepleted MDCKII cells respond to inhibition of HMG CoA reductase by increasing the amount of NPC1L1 expressed at the cell surface. This observation supports and extends an analysis of the NPC1L1 promoter indicating that the HMG CoA reductase inhibitor mevinolin up-regulates transcription of NPC1L1 in CaCo-2 cells (Alrefai et al., 2007) . It is noteworthy that this mechanism seems to be relevant only in cells grown in lipoprotein-depleted media, suggesting that under normal conditions, the acquisition of lipoproteins, cholesterol ester, and cholesterol through LDL receptor can bypass the need for up-regulating surface NPC1L1 levels. These observations support the contention that NPC1L1 may act as part of a cholesterol transport mechanism in MDCKII cells. However, unlike recent studies suggesting a rapid translocation of fluorescence-labeled human NPC1L1-GFP from inside the cell to the subapical membrane of McArdle RH7777 rat hepatoma cells (Yu et al., 2006; Brown et al., 2007) , there was no short-term increase (Ͻ8 h) in the number of [ 3 H]AS binding sites in MDCKII II cells upon challenging with lovastatin (data not shown), which is consistent with a transcriptional response (Alrefai et al., 2007) .
Although enterocytes and hepatocytes facilitate the transcellular flux of cholesterol (Huff et al., 2006; Davis and Veltri, 2007; Levy et al., 2007; Orlowski et al., 2007) , MDCKII cells are derived from the kidney distal convoluted tubule where the apical membrane faces the filtration fluid, and cholesterol flux has not been reported. Given these differences in transcellular cholesterol flux, it was important to determine whether MDCKII cells, although sensing and responding to variations in endogenous cholesterol, could actually transport cholesterol in an NPC1L1-dependent manner. Using an assay similar to that reported for monitoring EZE-sensitive cholesterol influx into McArdle RH7777 rat hepatoma cells overexpressing human NPC1L1 tagged with GFP (Yu et al., 2006) , cholesterol flux in the apical membrane of MDCKII cells, after cholesterol-depletion with ␤mCD, was not significantly sensitive to EZE (Yu et al., 2006) . These observations indicate that at a defined NPC1L1 site density of 4 ϫ 10 5 [ 3 H]AS sites/cell, there is not enough NPC1L1-dependent Ch influx into cells to overcome the endogenous incorporation of [ 3 H]Ch into the membrane of MDCKII cells. However, overexpression of dog or human NPC1L1 in MDCKII cells increases the amount of NPC1L1-mediated cholesterol influx relative to nonspecific delivery of cholesterol. Such an approach, in a manner similar to the overexpression of NPC1L1 in CaCo-2 cells (Yamanashi et al., 2007) 3 H]Ch flux through NPC1L1, we have been able to examine the pharmacological relationship between EZE analog binding to NPC1L1 and its effect on EZE analog sensitive cholesterol flux in vitro. It is remarkable that the IC 50 of EZE analog block of cholesterol flux for both dog and mouse NPC1L1 is virtually identical to the K d of EZE analog binding. This observation indicates a tight coupling between EZE analog binding and reduction in cholesterol flux, suggesting that mechanistically, EZE analogs reduce cholesterol flux through NPC1L1 by either competing directly with cholesterol to bind, presumably at the sterol-sensing domain (Radhakrishnan et al., 2004) or by altering critical conformational changes in NPC1L1 necessary for cholesterol flux. Discriminating between these hypotheses has critical implications for the design of novel NPC1L1 inhibitors.
